Tesamorelin
Also sold as Egrifta
About
About Tesamorelin
Tesamorelin is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy and is used off-label in optimization medicine for visceral fat reduction and cognitive enhancement. Clinical data shows significant reductions in visceral adipose tissue and emerging evidence suggests neuroprotective benefits in older adults. It produces stronger and more sustained GH elevation than sermorelin. Compounded versions are available through licensed pharmacies.
Science
Mechanism of Action
Binds GHRH receptors with high affinity and a stabilized structure that resists degradation, producing robust and sustained GH pulse amplification and downstream IGF-1 elevation.
Dosing
Typical Protocol
1–2 mg subcutaneous injection once daily in the evening.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Compare verified providers offering Tesamorelin
All 3 audited providers, ranked by Vial Check by default. Click any column to sort.
Compound comparisons
Compare Tesamorelin
Tesamorelin set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.